4-(3-phenylphenoxy)butanoic acid | 170638-89-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-phenylphenoxy)butanoic acid
• CAS: 170638-89-8
• 化学式: C₁₆H₁₆O₃
• 分子量: 256.301
• InChiKey: LALXRMLCEMDIHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-phenylphenoxy)butanoic acid 在 PPA 作用下， 以 xylene 为溶剂， 反应 4.0h， 以66%的产率得到3,4-Dihydro-8-phenyl-1-benzoxepin-5(2H)-one
  参考文献：
  名称：

  Synthesis and structure-activity relationships of new ACAT inhibitors

  摘要：

  A series of heterocyclic ureas were synthesized and their ability to inhibit arterial and intestinal ACAT was assessed in animals. The structural modifications carried out in this series led to N-2-(2,4-difluorophenyl)-N-1-8-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl-N-1-n-heptylurea 21, which proved to be very active on both the inhibition of aortic ACAT and the inhibition of rat cholesterol intestinal absorption, thus exhibiting a strong hypocholesterolemic effect po in the rat (ED(25) = 0.2 mg/kg).

  DOI：

  10.1016/0223-5234(96)88247-x
• 作为产物：
  描述：

  γ-丁内酯 、 间羟基联苯 在 sodium hydroxide 作用下， 生成 4-(3-phenylphenoxy)butanoic acid
  参考文献：
  名称：

  Synthesis and structure-activity relationships of new ACAT inhibitors

  摘要：

  A series of heterocyclic ureas were synthesized and their ability to inhibit arterial and intestinal ACAT was assessed in animals. The structural modifications carried out in this series led to N-2-(2,4-difluorophenyl)-N-1-8-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl-N-1-n-heptylurea 21, which proved to be very active on both the inhibition of aortic ACAT and the inhibition of rat cholesterol intestinal absorption, thus exhibiting a strong hypocholesterolemic effect po in the rat (ED(25) = 0.2 mg/kg).

  DOI：

  10.1016/0223-5234(96)88247-x

文献信息

• Biphenyl hydroxamate inhibitors of matrix metalloproteinases
  申请人：Abbott Laboratories

  公开号：US05665777A1

  公开（公告）日：1997-09-09

  Compounds of formula ##STR1## or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF.alpha. secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF.alpha. secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF.alpha. secretion.

  式为##STR1##的化合物或其药学上可接受的盐，能够抑制基质金属蛋白酶和TNFα分泌，对治疗炎症性疾病状态有用。还揭示了基质金属蛋白酶和TNFα分泌抑制组合物以及抑制基质金属蛋白酶和TNFα分泌的方法。
• BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Abbott Laboratories

  公开号：EP0874808A1

  公开（公告）日：1998-11-04
• US5665777A
  申请人：——

  公开号：US5665777A

  公开（公告）日：1997-09-09
• [EN] BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] INHIBITEURS DE METALLOPROTEINASES MATRICIELLES, A L'HYDROXAMATE BIPHENYLIQUE
  申请人：ABBOTT LABORATORIES

  公开号：WO1997018188A1

  公开（公告）日：1997-05-22

  (EN) Compounds of formula (I), or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF$g(a) secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF$g(a) secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF$g(a) secretion.(FR) L'invention concerne des composés de formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci, qui inhibent la sécrétion des métalloprotéinases matricielles et de TNF$g(a) et sont utiles dans le traitement de pathologies inflammatoires. Elle porte aussi sur des compositions inhibant la sécrétion de métalloprotéinases matricielles et de TNF$g(a) et sur une méthode d'inhibition de la sécrétion de métalloprotéinases matricielles et de TNF$g(a).
• Synthesis and structure-activity relationships of new ACAT inhibitors
  作者：JY Nioche、J Decerprit、D Festal

  DOI：10.1016/0223-5234(96)88247-x

  日期：1995.1

  A series of heterocyclic ureas were synthesized and their ability to inhibit arterial and intestinal ACAT was assessed in animals. The structural modifications carried out in this series led to N-2-(2,4-difluorophenyl)-N-1-8-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl-N-1-n-heptylurea 21, which proved to be very active on both the inhibition of aortic ACAT and the inhibition of rat cholesterol intestinal absorption, thus exhibiting a strong hypocholesterolemic effect po in the rat (ED(25) = 0.2 mg/kg).